At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope
Acute Myeloid Leukemia (AML), American Society of Hematology (ASH) Annual Meeting, Analysts, Bristol Myers Squibb, Business, CAR-T Therapy, CD47 Inhibitors, Chronic Lymphocytic Leukemia (CLL), Clinical Studies, Clinical Trials, CRISPR, Data, Gene Therapy, Janssen, Johnson & Johnson, Large B-Cell Lymphoma, Monoclonal Antibodies, New England Journal of Medicine, R&D, Sickle Cell Disease, Therapeutics, Transfusion-Dependent Beta-Thalassemia (TDT)The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.
Clarivate Plc released the company’s list of Highly Cited Researchers 2020 that identifies researchers who “demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.”
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.
The Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery and development of CRISPR gene editing.
Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.
Bristol-Myers Squibb is taking aim at harnessing CRISPR-based solutions to treat certain cancers with a $65 million collaboration with Montreal-based Repare Therapeutics.
Mammoth Strikes Deal with GSK Consumer Healthcare to Develop COVID-19 Test Using CRISPR-Based Platform
Asymptomatic Patients, Business, Cas-12 Enzyme, Collaborations, Coronavirus Disease 2019 (COVID-19), COVID-19 Infections, CRISPR, Deals, Diagnostic Tests, Nature Biotechnology, Papers, Polymerase Chain Reaction (PCR), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first patients in the companies’ Phase I/II clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001.